

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**MEDICAL TECHNOLOGIES EVALUATION  
PROGRAMME**

**Equality impact assessment – Guidance development**

**The 3M Tegaderm CHG IV securement dressing for  
central venous and arterial catheter insertion sites**

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

**Consultation**

- |                                                                                                                               |
|-------------------------------------------------------------------------------------------------------------------------------|
| 1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? |
|-------------------------------------------------------------------------------------------------------------------------------|

|                                                   |
|---------------------------------------------------|
| No equality issues were identified during scoping |
|---------------------------------------------------|

- |                                                                                                                                                                                      |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2. Have any other potential equality issues been highlighted in the company's submission, or patient organisation questionnaires, and, if so, how has the Committee addressed these? |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                                                                                             |
|---------------------------------------------------------------------------------------------|
| No equality issues were identified in the company's submissions or by patient organisations |
|---------------------------------------------------------------------------------------------|

- |                                                                                                                                 |
|---------------------------------------------------------------------------------------------------------------------------------|
| 3. Have any other potential equality issues been identified by the Committee and, if so, how has the Committee addressed these? |
|---------------------------------------------------------------------------------------------------------------------------------|

|                                                     |
|-----------------------------------------------------|
| No equality issues were identified by the Committee |
|-----------------------------------------------------|

- |                                                                                                                                                                                                                        |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to or difficulties with access for the |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                 |
|-----------------|
| specific group? |
| No              |

|                                                                                                                                                                               |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability? |
| No                                                                                                                                                                            |

|                                                                                                                                                                                                                                             |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to , or difficulties with access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality? |
| Not applicable                                                                                                                                                                                                                              |

|                                                                                                                                              |
|----------------------------------------------------------------------------------------------------------------------------------------------|
| 7. Have the Committee's considerations of equality issues been described in the medical technology consultation document, and, if so, where? |
| Not applicable – There were no equality issues that required consideration                                                                   |

**Approved by Associate Director (name):** Mark Campbell

**Date:** 11/03/2015

## Medical technologies guidance document

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No equality issues were raised during the consultation

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

Not applicable

3. If the recommendations have changed after consultation, is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

Not applicable

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

Not applicable

5. Have the Committee's considerations of equality issues been described in the medical technologies guidance document, and, if so, where?

Not applicable

**Approved by Programme Director (name):** Mirella Marlow

**Date:** 15/07/2015